Marinomed Competitors

Stocks . Austria . 
Stock . Marinomed Biotech AG
MARI Stock   19.00  0.20  1.06%   
Marinomed Biotech competes with RATH Aktiengesellscha, BAWAG Group, Semperit Aktiengesellscha, and Oesterr Post; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing Marinomed Biotech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Marinomed Biotech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Marinomed Biotech Correlation with its peers.

Marinomed Biotech vs IShares ATX Correlation

Pay attention - limited upside

The correlation between Marinomed Biotech AG and EX01 is -0.86 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Marinomed Biotech AG and EX01 in the same portfolio, assuming nothing else is changed.

Moving together with Marinomed Stock

  0.68JD JD IncPairCorr

Moving against Marinomed Stock

  0.87VIG Vienna InsurancePairCorr
  0.85SAN Banco Santander SAPairCorr
  0.84BG BAWAG Group AGPairCorr
  0.82EBS Erste Group BankPairCorr
  0.81RBI Raiffeisen Bank IntePairCorr
Hype
Prediction
LowEstimatedHigh
17.7119.0020.29
Details
Intrinsic
Valuation
LowRealHigh
14.9216.2120.90
Details
Naive
Forecast
LowNextHigh
18.0119.3020.60
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
18.4018.9719.54
Details

Marinomed Biotech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Marinomed Biotech and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Marinomed and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Marinomed Biotech does not affect the price movement of the other competitor.

High positive correlations

EX01
+ 0.98
BG
POST
+ 0.93
BG
EX01
+ 0.92
POST
EX01
+ 0.91
VOE
VOE
+ 0.85
BG
BHD
+ 0.85
ABIN
  

High negative correlations

EX01
- 0.86
MARI
VOE
- 0.85
MARI
BG
- 0.84
MARI
POST
- 0.82
MARI
ABIN
- 0.67
MARI
BHD
- 0.63
MARI

Risk-Adjusted Indicators

There is a big difference between Marinomed Stock performing well and Marinomed Biotech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Marinomed Biotech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
MARI  0.90 (0.05) 0.00  0.23  0.00 
 0.00 
 2.04 
(2.15)
 7.40 
RAT  1.13  0.09  0.01  0.30  1.54 
(7.60)
 3.60 
(3.48)
 19.55 
BG  1.01  0.33  0.14 (1.71) 1.21 
(1.16)
 2.29 
(1.70)
 5.81 
SEM  1.27 (0.09) 0.00 (0.05) 0.00 
 0.00 
 2.59 
(3.13)
 9.61 
POST  0.73  0.14  0.07  0.67  0.74 
(0.88)
 1.86 
(1.24)
 7.60 
ABIN  1.04  0.19  0.06 (4.23) 1.27 
(1.13)
 2.51 
(2.02)
 6.62 
BHD  1.13  0.14  0.03  0.23  1.41 
(3.98)
 4.17 
(2.70)
 15.00 
LNZ  1.70  0.07 (0.01)(0.70) 2.48 
(1.73)
 3.60 
(3.84)
 13.75 
VOE  1.37  0.36  0.21  1.74  1.05 
(1.68)
 3.12 
(2.30)
 10.98 
EX01  0.75  0.23  0.14  1.01  0.76 
(0.84)
 1.88 
(1.22)
 7.02 

Marinomed Biotech Competitive Analysis

The better you understand Marinomed Biotech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Marinomed Biotech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Marinomed Biotech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MARI RAT BG SEM POST ABIN BHD LNZ VOE EX01
 1.06 
 19.00 
Marinomed
 13.64 
 25.00 
RATH
 0.59 
 137.30 
BAWAG
 3.37 
 12.60 
Semperit
 1.71 
 32.80 
Oesterr
 0.27 
 59.24 
Anheuser
 0.58 
 86.00 
Burgenland
 4.25 
 25.75 
Lenzing
 2.74 
 40.44 
Voestalpine
 3.10 
 59.26 
IShares
Market Volatility
(90 Days Market Risk)
Very steady
Not too volatile
Very steady
Not too volatile
Very steady
Very steady
Very steady
Not too volatile
Very steady
Very steady
Market Performance
(90 Days Performance)
Weakest
Soft
Strong
Weakest
Good
Good
Fair
Weakest
Solid
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Average
Low
Low
Small
Low
Low
Small
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Buy
Strong Hold
Strong Hold
Strong Sell
Strong Hold
Strong Sell
Strong Buy
Strong Buy
Current Ratio
N/A
2.7
N/A
N/A
0.98
0.54
7.2
N/A
N/A
N/A
Net Asset
21.34 M
113.75 M
56.33 B
958.58 M
4.79 B
217.63 B
80.72 M
5.32 B
17.02 B
93.66 M
Profit Margin
-0.41
0.0262
0.42
-0.0103
0.0522
0.0888
N/A
0.0263
0.0782
N/A
EBITDA
(3.58 M)
13.59 M
N/A
349.72 M
401.1 M
18.75 B
N/A
386.85 M
2.09 B
N/A
Operating Margin
-0.28
0.0263
0.43
0.0623
0.068
0.25
N/A
0.0467
0.0893
N/A
Current Valuation
104.48 M
73.15 M
11.1 B
256.92 M
1.33 B
184.84 B
298.29 M
2.59 B
6.58 B
N/A
Price To Book
586.32
0.74
1.01
0.74
3.52
1.65
3.47
0.92
0.6
1.04
Five Year Return
N/A
3.19
N/A
N/A
5.89
N/A
4.86
N/A
N/A
7.43
One Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-5.58
Beta
0.2
0.0826
1.12
0.84
0.41
1.1
0.15
1.22
1.52
N/A
Number Of Employees
36
583
3.21 K
6.7 K
27.16 K
169 K
4
8.43 K
50.02 K
N/A
Equity Positions Weight
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
98.12
Shares Outstanding
1.51 M
1.5 M
82.5 M
20.57 M
67.55 M
1.7 B
3 M
26.55 M
177.06 M
N/A
Three Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
15.46
Cash Flow From Operations
(4.87 M)
2.45 M
312 M
289.23 M
493.3 M
14.8 B
10.36 M
394.03 M
1.24 B
N/A
Annual Yield
N/A
0.0127
0.0516
0.068
0.0569
0.0091
0.0379
0.0629
0.037
N/A
Total Debt
15.01 M
21.7 M
7.64 B
51.69 M
N/A
85.54 B
972 K
N/A
2.32 B
N/A
Return On Equity
-3.95
0.0542
0.0847
-0.009
0.2
0.0679
0.13
0.0281
0.16
N/A
Z Score
2.4
0.6
N/A
6.4
N/A
0.6
N/A
N/A
1.2
N/A
Return On Asset
-0.11
0.0157
0.0064
0.0467
0.0263
0.0419
-0.0027
0.0135
0.0626
N/A
Book Value Per Share
-2.32
35.34
47.34
23.97
9.48
36.09
26.88
72.39
41.75
N/A
Total Asset
21.34 M
113.75 M
56.33 B
958.58 M
4.79 B
217.63 B
80.72 M
5.32 B
17.02 B
93.66 M
Target Price
92.9
N/A
70.55
24.4
27.83
N/A
N/A
69.75
27.03
N/A
Debt To Equity
N/A
0.85
N/A
N/A
0.45
144.3
1.2
N/A
N/A
N/A
Last Dividend Paid
N/A
0.33
N/A
1.5
1.9
0.57
3.45
4.35
1.2
N/A
Shares Owned By Institutions
22.25
N/A
66.58
11.6
14.62
14.29
N/A
15.87
27.83
N/A
Market Capitalization
66.98 M
39 M
4.62 B
467.02 M
2.25 B
107.71 B
276 M
1.85 B
5.75 B
N/A
Price To Earning
N/A
24.77
14.56
N/A
18.12
23.33
21.32
N/A
N/A
13.05
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
1.31
N/A
N/A
N/A
N/A
Price To Sales
6.6
0.36
5.11
0.32
0.87
1.96
26.33
0.63
0.25
0.75
Net Income
(5.89 M)
4.31 M
479.9 M
246.99 M
152.3 M
4.67 B
10.3 M
110.35 M
1.3 B
N/A
Earnings Per Share
-4.0
1.89
5.68
5.14
1.93
2.31
3.43
2.55
5.92
N/A
Shares Owned By Insiders
37.9
89.5
2.29
64.24
52.85
48.66
90.26
56.8
30.0
N/A
Revenue
11.63 M
97.84 M
1.32 B
1.18 B
2.52 B
54.3 B
N/A
2.19 B
14.92 B
N/A
Ten Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
5.97
Cash And Equivalents
N/A
16.86 M
1.17 B
N/A
231.7 M
8.27 B
10 K
N/A
N/A
N/A
Cash Per Share
N/A
11.24
13.28
N/A
3.43
4.22
N/A
N/A
N/A
N/A
Gross Profit
1.2 M
51.87 M
1.01 B
679.27 M
573.1 M
31.21 B
N/A
499.61 M
3.36 B
N/A
Day Typical Price
19.0
25.0
138.3
12.6
32.63
59.15
86.0
25.47
40.07
59.04
Accumulation Distribution
N/A
N/A
4032.25
64.42
808.66
0.8
N/A
2862.3
13282.16
0.0147
Market Facilitation Index
N/A
N/A
0.0
1.0E-4
0.0
0.0014
N/A
0.0
0.0
0.87
Daily Balance Of Power
9.2 T
9.2 T
0.2667
(1.57)
0.9167
0.6154
0
1.0
0.9643
2.045977
Period Momentum Indicator
0.2
3.0
0.8
(0.44)
0.55
0.16
(0.50)
1.05
1.08
1.78
Rate Of Daily Change
1.01
1.14
1.01
0.97
1.02
1.0
0.99
1.04
1.03
1.03
Day Median Price
19.0
25.0
138.8
12.6
32.55
59.11
86.0
25.33
39.88
58.94
Price Action Indicator
0.1
1.5
(1.10)
(0.22)
0.52
0.21
(0.25)
0.95
1.1
1.21
Relative Strength Index
46.98
70.61
73.51
45.31
61.8
63.96
66.95
56.92
63.95
71.36
Coefficient Of Variation
(1,956)
2115.43
435.17
(7,077)
594.38
692.57
987.73
3126.34
481.17
413.07
Mean Deviation
0.8964
1.13
1.01
1.27
0.7314
1.04
1.13
1.7
1.37
0.7503
Jensen Alpha
(0.05)
0.0919
0.3271
(0.09)
0.1432
0.1902
0.1404
0.0741
0.3579
0.2268
Total Risk Alpha
(0.24)
(0.25)
0.1327
(0.26)
0.0329
0.0132
(0.07)
(0.23)
0.1405
0.1133
Sortino Ratio
N/A
0.0078
0.1378
N/A
0.0684
0.0633
0.0339
(0.01)
0.2123
0.1374
Downside Variance
N/A
25.29
2.46
N/A
1.12
2.11
17.65
7.13
1.79
1.29
Standard Deviation
1.29
3.03
1.39
1.77
1.05
1.36
2.43
2.36
1.87
1.07
Kurtosis
2.04
14.94
4.58
1.48
3.77
0.3733
11.92
1.53
3.6
3.19
Potential Upside
2.04
3.6
2.29
2.59
1.86
2.51
4.17
3.6
3.12
1.88
Treynor Ratio
0.2325
0.3022
(1.71)
(0.05)
0.6701
(4.23)
0.2317
(0.70)
1.74
1.01
Maximum Drawdown
7.4
19.55
5.81
9.61
7.6
6.62
15.0
13.75
10.98
7.02
Variance
1.66
9.2
1.94
3.13
1.1
1.84
5.92
5.55
3.49
1.15
Market Risk Adjusted Performance
0.2425
0.3122
(1.70)
(0.04)
0.6801
(4.22)
0.2417
(0.69)
1.75
1.02
Risk Adjusted Performance
(0.03)
0.0425
0.1744
(0)
0.1272
0.1112
0.0817
0.0305
0.1595
0.1819
Skewness
0.7056
2.73
(1.31)
0.4913
0.018
(0.30)
1.38
(0.46)
1.22
(0.34)
Semi Deviation
N/A
1.54
1.21
N/A
0.7429
1.27
1.41
2.48
1.05
0.7557
Information Ratio
(0.13)
0.013
0.1551
(0.07)
0.0691
0.0678
0.0585
(0.01)
0.1522
0.1453
Value At Risk
(2.15)
(3.48)
(1.70)
(3.13)
(1.24)
(2.02)
(2.70)
(3.84)
(2.30)
(1.22)
Expected Short fall
N/A
(7.60)
(1.16)
N/A
(0.88)
(1.13)
(3.98)
(1.73)
(1.68)
(0.84)
Downside Deviation
N/A
5.03
1.57
N/A
1.06
1.45
4.2
2.67
1.34
1.14
Semi Variance
N/A
2.38
1.47
N/A
0.552
1.62
2.0
6.13
1.1
0.5711

Marinomed Biotech Competition Performance Charts

Five steps to successful analysis of Marinomed Biotech Competition

Marinomed Biotech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Marinomed Biotech in relation to its competition. Marinomed Biotech's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Marinomed Biotech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Marinomed Biotech's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Marinomed Biotech, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Marinomed Biotech position

In addition to having Marinomed Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Most Shorted Equities Thematic Idea Now

Most Shorted Equities
Most Shorted Equities Theme
Dynamically calculated list of top equities currently trending upward via a buy-out by investors. The Most Shorted Equities theme has 257 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Most Shorted Equities Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Marinomed Stock

Marinomed Biotech financial ratios help investors to determine whether Marinomed Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marinomed with respect to the benefits of owning Marinomed Biotech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY